Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it alot easier for you and your company.

This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process of drug development offers you and your company clear opportunities. This emerging field is generating interest from the healthcare industry and regulatory bodies, with the associated market expanding continually as the importance of theranostics is recognised.

Theranostic solutions are playing an increasingly important role in pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, theranostics is paving the way towards the long-held goal of personalised medicine, to the benefit of patients and payers. Theranostics has also received encouraging support from regulators such as the FDA. Pharmaceutical, diagnostics and biotechnological companies cannot afford to overlook this rapidly emerging field. So you should be sure you corner your percentage of the market immediately.

Theranostics 2007-2012 examines the market for theranostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses theranostics in the context of the wider diagnostics market. In addition to consultation with experts in industry, this research involved a detailed study of documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting and SWOT analyses. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, this report concentrates on the following essential aspects of the theranostics sector:

• Technologies that drive the theranostics sector
• Key industrial players in theranostics – including partnerships in that field
• Forecasts of the global theranostics market from 2007-2012, including forecasts of the molecular diagnostics market and principal market segments within theranostics
• Drivers and opportunities in the theranostics sector
• Restraints and threats in the theranostics sector
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of future trends in the sector
• Insight from a survey with experts from industry and academia

Why you should buy this report: 

• To receive a comprehensive analysis of the prospects for theranostics from 2007-2012
• To discover predicted revenues, growth rates and other key metrics for theranostic solutions from 2006-2011
• To receive the views of experts in the theranostics sector
• To determine the forces that influence the market for theranostics: Competitive characteristics of the market, Drivers, Restraints, Strengths, weaknesses, opportunities and threats
• To find out where theranostics is heading - both technologically and commercially

Visiongain predicts that all aspects of theranostics will exhibit strong growth in revenues from 2007-2012, with significant investments being made by far-sighted companies in the pharmaceutical, diagnostics and biotechnological sectors. Although still in its early stages of commercial development, theranostics will increasingly gain acceptance from stakeholders in healthcare. Successful participating companies will benefit as a result, gaining early market prominence from high-value products. But which areas of theranostics will that be? Find out today by ordering your executive copy of Theranostics 2007.